Showing results (51-60 of 98) with videos related to
Sort By:
Pageof 10
Cell Death Discovery|April 21, 2022
The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXASandra Weller, Astrid Toennießen, Benjamin Schaefer, et al.Cancers|January 26, 2024
Lung Cancer Related Thrombosis (LCART): Focus on Immune Checkpoint BlockadeAndriani Charpidou, Grigorios Gerotziafas, Sanjay Popat, et al.Cell Death & Disease|August 26, 2020
The BCL-2 selective inhibitor ABT-199 sensitizes soft tissue sarcomas to proteasome inhibition by a concerted mechanism requiring BAX and NOXAAlina Muenchow, Sandra Weller, Clemens Hinterleitner, et al.Frontiers in Immunology|September 28, 2020
Genetic Loss of LCK Kinase Leads to Acceleration of Chronic Lymphocytic LeukemiaMelanie Märklin, Alexander R Fuchs, Claudia Tandler, et al.Journal of Leukocyte Biology|December 18, 2018
Loss of NFAT2 expression results in the acceleration of clonal evolution in chronic lymphocytic leukemiaDavid J Müller, Stefan Wirths, Alexander R Fuchs, et al.Frontiers in Immunology|May 3, 2021
Bispecific NKG2D-CD3 and NKG2D-CD16 Fusion Proteins as Novel Treatment Option in Advanced Soft Tissue SarcomasIlona Hagelstein, Martina S Lutz, Moritz Schmidt, et al.Journal of Virology|January 11, 2013
Innate immune defense defines susceptibility of sarcoma cells to measles vaccine virus-based oncolysisSusanne Berchtold, Johanna Lampe, Timo Weiland, et al.Journal of Cancer Research and Clinical Oncology|April 4, 2014
First salvage treatment in patients with advanced germ cell cancer after cisplatin-based chemotherapy: analysis of a registry of the German Testicular Cancer Study Group (GTCSG)Lars Arne Berger, Carsten Bokemeyer, Anja Lorch, et al.Clinical Pharmacology and Therapeutics|October 11, 2025
Clinical Implementation of Pharmacogenomics and Drug-Drug Interaction Screening in a German Academic Teaching Hospital and Outpatient Follow-UpRoman Tremmel, Filippa Schreeck, Simon Jaeger, et al.Cancer Immunology, Immunotherapy : CII|March 21, 2018
The novel deubiquitinase inhibitor b-AP15 induces direct and NK cell-mediated antitumor effects in human mantle cell lymphomaKorbinian N Kropp, Stefanie Maurer, Kathrin Rothfelder, et al.Pageof 10